Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA 02115, USA.
Division of Molecular Medicine, Children's Hospital, Boston, MA 02115, USA.
Int J Mol Sci. 2024 Sep 13;25(18):9913. doi: 10.3390/ijms25189913.
The present study analyzes two potential therapeutic approaches for Alzheimer's disease (AD). One is the suppression of the neuronal integrated stress response (ISR). Another is the targeted degradation of intraneuronal amyloid-beta (Aβ) via the activation of BACE1 (Beta-site Aβ-protein-precursor Cleaving Enzyme) and/or BACE2. Both approaches are rational. Both are promising. Both have substantial intrinsic limitations. However, when combined in a carefully orchestrated manner into a composite therapy they display a prototypical synergy and constitute the apparently optimal, potentially most effective therapeutic strategy for AD.
本研究分析了两种潜在的阿尔茨海默病(AD)治疗方法。一种是抑制神经元整合应激反应(ISR)。另一种是通过激活 BACE1(β-位淀粉样前体蛋白裂解酶 1)和/或 BACE2,靶向降解神经元内的淀粉样β(Aβ)。这两种方法都是合理的。这两种方法都是有前途的。这两种方法都有实质性的内在局限性。然而,当以一种精心协调的方式组合成一种综合疗法时,它们表现出典型的协同作用,构成了 AD 显然最佳、最有效的潜在治疗策略。
J Alzheimers Dis Rep. 2023-1-19
J Alzheimers Dis. 2024
Ageing Res Rev. 2023-11
JAMA Netw Open. 2023-9-5